NYSE:CMD - Cantel Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $71.50
  • Forecasted Upside: -11.01 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$80.35
▲ +0.37 (0.46%)
1 month | 3 months | 12 months
Get New Cantel Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$71.50
▼ -11.01% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Cantel Medical in the last 3 months. The average price target is $71.50, with a high forecast of $100.00 and a low forecast of $51.00. The average price target represents a -11.01% upside from the last price of $80.35.
Hold
The current consensus among 4 investment analysts is to hold stock in Cantel Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Needham & Company LLCDowngradeBuy ➝ HoldMedium
i
1/12/2021SidotiDowngradeBuy ➝ NeutralMedium
i
12/10/2020SidotiBoost Price Target$72.00 ➝ $100.00Low
i
10/23/2020CJS SecuritiesInitiated CoverageOutperform$70.00Low
i
8/19/2020Bank of AmericaInitiated CoverageUnderperform$51.00High
i
8/6/2020Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Michael Matson at Needham & Company LLC
6/4/2020Needham & Company LLCInitiated CoverageBuy$65.00N/A
i
Rating by Michael Matson at Needham & Company LLC
5/12/2020Needham & Company LLCLower Price TargetBuy$75.00 ➝ $65.00N/A
i
Rating by Michael Matson at Needham & Company LLC
4/14/2020SidotiLower Price TargetBuy$84.00 ➝ $65.00N/A
i
2/18/2020SidotiLower Price TargetBuy$116.00 ➝ $108.00N/A
i
2/11/2020Needham & Company LLCLower Price TargetBuy$94.00 ➝ $82.00High
i
12/10/2019Needham & Company LLCReiterated RatingBuy$94.00N/A
i
Rating by Michael Matson at Needham & Company LLC
11/26/2019Needham & Company LLCUpgradeHold ➝ Buy$94.00N/A
i
9/24/2019Raymond JamesReiterated RatingHoldN/A
i
Rating by Lawrence Keusch at Raymond James
6/11/2019Needham & Company LLCReiterated RatingHoldN/A
i
3/5/2019Needham & Company LLCReiterated RatingHoldN/A
i
3/1/2019Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
9/28/2018SidotiLower Price TargetBuy$142.00 ➝ $120.00Low
i
9/28/2018Raymond JamesLower Price TargetOutperform$115.00 ➝ $108.00Low
i
9/28/2018SidotiSet Price TargetBuy ➝ Buy$142.00 ➝ $120.00N/A
i
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$115.00N/A
i
12/7/2017Needham & Company LLCReiterated RatingHoldN/A
i
12/4/2017Raymond JamesReiterated RatingHoldN/A
i
9/1/2017Needham & Company LLCReiterated RatingHoldMedium
i
8/2/2017SidotiUpgradeNeutral ➝ Buy$92.00High
i
Rating by Mitra Ramgopal at Sidoti
6/9/2017BenchmarkDowngradeBuy ➝ HoldHigh
i
6/8/2017Needham & Company LLCReiterated RatingHoldHigh
i
3/17/2017Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformLow
i
12/9/2016BenchmarkLower Price TargetBuy$100.00 ➝ $83.00N/A
i
Rating by Raymond Myers at Benchmark Co.
12/9/2016BenchmarkBoost Price TargetBuy$83.00 ➝ $100.00N/A
i
10/1/2016BenchmarkSet Price TargetBuy$83.00N/A
i
Rating by Raymond Myers at Benchmark Co.
8/29/2016BenchmarkInitiated CoverageBuy$83.00 ➝ $83.00N/A
i
8/24/2016Needham & Company LLCInitiated CoverageHoldN/A
i
(Data available from 1/20/2016 forward)
Cantel Medical logo
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
Read More

Today's Range

Now: $80.35
$79.93
$81.00

50 Day Range

MA: $79.18
$76.17
$84.66

52 Week Range

Now: $80.35
$20.81
$89.10

Volume

541,801 shs

Average Volume

763,489 shs

Market Capitalization

$3.39 billion

P/E Ratio

95.66

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Cantel Medical?

The following sell-side analysts have issued stock ratings on Cantel Medical in the last twelve months: Bank of America Co., CJS Securities, Needham & Company LLC, Sidoti, and Zacks Investment Research.

What is the current price target for Cantel Medical?

4 Wall Street analysts have set twelve-month price targets for Cantel Medical in the last year. Their average twelve-month price target is $71.50, suggesting a possible downside of 11.0%. Sidoti has the highest price target set, predicting CMD will reach $100.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $51.00 for Cantel Medical in the next year.

What is the current consensus analyst rating for Cantel Medical?

Cantel Medical currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CMD, but not buy more shares or sell existing shares.

What other companies compete with Cantel Medical?

How do I contact Cantel Medical's investor relations team?

Cantel Medical's physical mailing address is 150 CLOVE ROAD, LITTLE FALLS NJ, 07424. The company's listed phone number is 973-890-7220 and its investor relations email address is investorrelations@cantelmedical.com. The official website for Cantel Medical is www.cantelmedical.com.